Information Provided By: 
Fly News Breaks for May 23, 2018
KOOL
May 23, 2018 | 07:04 EDT
H.C. Wainwright analyst Swayampakula Ramakanth started Cesca Therapeutics with a Buy rating and $1.50 price target. Cesca currently markets a range of cell processing products in the U.S. and China, which should continue to provide a steady revenue stream, Ramakanth tells investors in a research note. The analyst believes the company's CAR-TXpress could significantly reduce the time and cost of CAR-T manufacturing.
News For KOOL From the Last 2 Days
There are no results for your query KOOL
